Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriana C Rossi

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Blood Advances|February 23, 2019
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myelomaTomer M Mark, Peter A Forsberg, Adriana C Rossi, et al.
Bone Marrow Transplantation|May 3, 2025
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myelomaDarren Pan, Tarek H Mouhieddine, Tianxiang Sheng, et al.
Leukemia & Lymphoma|March 1, 2014
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myelomaTomer M Mark, Isaac A Bowman, Adriana C Rossi, et al.
American Journal of Clinical Pathology|July 25, 2020
Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative HistiocytosisMarc J Braunstein, Kseniya Petrova-Drus, Cara A Rosenbaum, et al.
Leukemia & Lymphoma|November 1, 2018
Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scalesJason Tay, Ravi Vij, Maxim Norkin, et al.
American Journal of Hematology|August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
American Journal of Hematology|February 12, 2019
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2025
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapyZachary M Avigan, Jerrel Catlett, Saoirse Bodnar, et al.
JCI Insight|May 5, 2026
Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myelomaSridevi Rajeeve, Matt Wilkes, Nicole Zahradka, et al.
Blood|June 3, 2026
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myelomaSusan Bal, Myo Htut, Omar Nadeem, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Blood Advances|February 23, 2019
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myelomaTomer M Mark, Peter A Forsberg, Adriana C Rossi, et al.
Bone Marrow Transplantation|May 3, 2025
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myelomaDarren Pan, Tarek H Mouhieddine, Tianxiang Sheng, et al.
Leukemia & Lymphoma|March 1, 2014
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myelomaTomer M Mark, Isaac A Bowman, Adriana C Rossi, et al.
American Journal of Clinical Pathology|July 25, 2020
Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative HistiocytosisMarc J Braunstein, Kseniya Petrova-Drus, Cara A Rosenbaum, et al.
Leukemia & Lymphoma|November 1, 2018
Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scalesJason Tay, Ravi Vij, Maxim Norkin, et al.
American Journal of Hematology|August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
American Journal of Hematology|February 12, 2019
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2025
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapyZachary M Avigan, Jerrel Catlett, Saoirse Bodnar, et al.
JCI Insight|May 5, 2026
Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myelomaSridevi Rajeeve, Matt Wilkes, Nicole Zahradka, et al.
Blood|June 3, 2026
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myelomaSusan Bal, Myo Htut, Omar Nadeem, et al.
Pageof 2